Skip to main content
SpringerLink
Log in

Epidemiology of Thyroid Cancer

  • Chapter
  • First Online:
Evidence-Based Endocrine Surgery

  • 603 Accesses

Abstract

Thyroid cancer is the most common endocrine malignancy, with an estimated incidence of 14.2 per 100,000 per year in the USA. This incidence of thyroid cancer is increasing worldwide, and is now the eighth most common malignancy in women in Singapore. The rise in thyroid cancer was mainly seen in the papillary subtype, with the incidence of follicular and anaplastic thyroid cancer remaining unchanged. Factors that may explain the variability in thyroid cancer incidence across the world include those of genetic factors, environmental factors, and access to health care. This chapter summarizes the epidemiology and management of papillary thyroid cancer (PTC) and analyzes the changing incidence of PTC and the etiologic factors that may be responsible for this trend.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shulin JH, Aizhen J, Kuo SM, Tan WB, Ngiam KY, Parameswaran R. Rising incidence of thyroid cancer in Singapore not solely due to micropapillary subtype. Ann R Coll Surg Engl. 2018;100(4):295–300.

    Article  CAS  Google Scholar 

  2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.

    Article  CAS  Google Scholar 

  3. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177(11):1357–61.

    Article  Google Scholar 

  4. Colonna M, Guizard AV, Schvartz C, Velten M, Raverdy N, Molinie F, et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000). Eur J Cancer. 2007;43(5):891–900.

    Article  CAS  Google Scholar 

  5. Burgess JR. Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982–1997). Thyroid. 2002;12(2):141–9.

    Article  Google Scholar 

  6. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.

    Article  Google Scholar 

  7. Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, Angelos P, Grogan RH. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Ann Surg Oncol. 2013;20(8):2746–53.

    Article  Google Scholar 

  8. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317–22.

    Article  Google Scholar 

  9. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62(2):118–28.

    Article  Google Scholar 

  10. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”—screening and overdiagnosis. N Engl J Med. 2014;371(19):1765–7.

    Article  Google Scholar 

  11. Grodski S, Brown T, Sidhu S, Gill A, Robinson B, Learoyd D, et al. Increasing incidence of thyroid cancer is due to increased pathologic detection. Surgery. 2008;144(6):1038–43. discussion 43

    Article  Google Scholar 

  12. Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S. The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. Thyroid. 2015;25(10):1127–36.

    Article  Google Scholar 

  13. Lee JH, Shin SW. Overdiagnosis and screening for thyroid cancer in Korea. Lancet. 2014;384(9957):1848.

    Article  Google Scholar 

  14. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomark Prev. 2009;18(3):784–91.

    Article  Google Scholar 

  15. Rego-Iraeta A, Perez-Mendez LF, Mantinan B, Garcia-Mayor RV. Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid. 2009;19(4):333–40.

    Article  Google Scholar 

  16. Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer. 2011;117(19):4390–5.

    Article  CAS  Google Scholar 

  17. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v214–9.

    Article  Google Scholar 

  18. Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136(9):2187–95.

    Article  Google Scholar 

  19. Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery. 2010;148(6):1147–52. discussion 52–3

    Article  Google Scholar 

  20. Husson O, Haak HR, van Steenbergen LN, Nieuwlaat WA, van Dijk BA, Nieuwenhuijzen GA, et al. Rising incidence, no change in survival and decreasing mortality from thyroid cancer in The Netherlands since 1989. Endocr Relat Cancer. 2013;20(2):263–71.

    Article  Google Scholar 

  21. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.

    Article  Google Scholar 

  22. Poljak NK, Kontic M, Colovic Z, Jeroncic I, Russo A, Mulic R. Does life along the sea carry greater risk of thyroid cancer? Coll Antropol. 2012;36(2):431–9.

    PubMed  Google Scholar 

  23. Smailyte G, Miseikyte-Kaubriene E, Kurtinaitis J. Increasing thyroid cancer incidence in Lithuania in 1978-2003. BMC Cancer. 2006;6:284.

    Article  Google Scholar 

  24. Colonna M, Grosclaude P, Remontet L, Schvartz C, Mace-Lesech J, Velten M, et al. Incidence of thyroid cancer in adults recorded by French cancer registries (1978–1997). Eur J Cancer. 2002;38(13):1762–8.

    Article  CAS  Google Scholar 

  25. Roche LM, Niu X, Pawlish KS, Henry KA. Thyroid cancer incidence in New Jersey: time trend, birth cohort and socioeconomic status analysis (1979-2006). J Environ Public Health. 2011;2011:850105.

    Article  Google Scholar 

  26. Ahn HS, Kim HJ, Kim KH, Lee YS, Han SJ, Kim Y, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26(11):1535–40.

    Article  Google Scholar 

  27. Tsuda T, Tokinobu A, Yamamoto E, Suzuki E. Thyroid cancer detection by ultrasound among residents ages 18 years and younger in Fukushima, Japan: 2011 to 2014. Epidemiology. 2016;27(3):316–22.

    Article  Google Scholar 

  28. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer. 1985;56(3):531.

    Article  CAS  Google Scholar 

  29. Leboulleux S, Tuttle RM, Pacini F, Schlumberger M. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 2016;4(11):933–42.

    Article  Google Scholar 

  30. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–9.

    Article  Google Scholar 

  31. Baker LC, Atlas SW, Afendulis CC. Expanded use of imaging technology and the challenge of measuring value. Health Aff (Millwood). 2008;27(6):1467–78.

    Article  Google Scholar 

  32. Rao VM, Levin DC, Parker L, Frangos AJ, Sunshine JH. Trends in utilization rates of the various imaging modalities in emergency departments: nationwide Medicare data from 2000 to 2008. J Am Coll Radiol. 2011;8(10):706–9.

    Article  Google Scholar 

  33. Youserm DM, Huang T, Loevner LA, Langlotz CP. Clinical and economic impact of incidental thyroid lesions found with CT and MR. Am J Neuroradiol. 1997;18(8):1423–8.

    CAS  PubMed  Google Scholar 

  34. Cronan JJ. Thyroid nodules: is it time to turn off the US machines? Radiology. 2008;247(3):602–4.

    Article  Google Scholar 

  35. Ross DS. Editorial: predicting thyroid malignancy. J Clin Endocrinol Metab. 2006;91(11):4253–5.

    Article  CAS  Google Scholar 

  36. Zagzag J, Kenigsberg A, Patel KN, Heller KS, Ogilvie JB. Thyroid cancer is more likely to be detected incidentally on imaging in private hospital patients. J Surg Res. 2017;215:239–44.

    Article  Google Scholar 

  37. Morris LG. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg. 2010;200(4):454–61.

    Article  Google Scholar 

  38. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141(3):259–77.

    Article  CAS  Google Scholar 

  39. Lubin JH, Adams MJ, Shore R, Holmberg E, Schneider AB, Hawkins MM, et al. Thyroid cancer following childhood low-dose radiation exposure: a pooled analysis of nine cohorts. J Clin Endocrinol Metab. 2017;102(7):2575–83.

    Article  Google Scholar 

  40. Jacob P, Bogdanova TI, Buglova E, Chepurniy M, Demidchik Y, Gavrilin Y, et al. Thyroid cancer risk in areas of Ukraine and Belarus affected by the Chernobyl accident. Radiat Res. 2006;165(1):1–8.

    Article  CAS  Google Scholar 

  41. Yamashita S, Thomas G. Thyroid cancer and nuclear accidents: long-term aftereffects of Chernobyl and Fukushima. London: Academic Press; 2017.

    Google Scholar 

  42. Mettler FA Jr, Thomadsen BR, Bhargavan M, Gilley DB, Gray JE, Lipoti JA, et al. Medical radiation exposure in the U.S. in 2006: preliminary results. Health Phys. 2008;95(5):502–7.

    Article  CAS  Google Scholar 

  43. Nikiforov YE. Is ionizing radiation responsible for the increasing incidence of thyroid cancer? Cancer. 2010;116(7):1626–8.

    Article  Google Scholar 

  44. Hahn K, Schnell-Inderst P, Grosche B, Holm LE. Thyroid cancer after diagnostic administration of iodine-131 in childhood. Radiat Res. 2001;156(1):61–70.

    Article  CAS  Google Scholar 

  45. Dickman PW, Holm LE, Lundell G, Boice JD Jr, Hall P. Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer. 2003;106(4):580–7.

    Article  CAS  Google Scholar 

  46. Nagataki S, Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid. 2002;12(10):889–96.

    Article  Google Scholar 

  47. Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P, Gomez I. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid. 1998;8(12):1179–83.

    Article  CAS  Google Scholar 

  48. Franceschi S. Iodine intake and thyroid carcinoma--a potential risk factor. Exp Clin Endocrinol Diabetes. 1998;106(Suppl 3):S38–44.

    CAS  PubMed  Google Scholar 

  49. Delange F, Lecomte P. Iodine supplementation: benefits outweigh risks. Drug Saf. 2000;22(2):89–95.

    Article  CAS  Google Scholar 

  50. Weissel M. Legal augmentation of iodine content in table salt from 10 to 20 mg KI/kg: documented effects a decade later. Exp Clin Endocrinol Diabetes. 2003;111(4):187–90.

    Article  CAS  Google Scholar 

  51. Dijkstra B, Prichard RS, Lee A, Kelly LM, Smyth PP, Crotty T, et al. Changing patterns of thyroid carcinoma. Ir J Med Sci. 2007;176(2):87–90.

    Article  CAS  Google Scholar 

  52. Harach HR, Escalante DA, Onativia A, Lederer Outes J, Saravia Day E, Williams ED. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinol. 1985;108(1):55–60.

    Article  CAS  Google Scholar 

  53. Verkooijen HM, Fioretta G, Pache JC, Franceschi S, Raymond L, Schubert H, et al. Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. Cancer Causes Control. 2003;14(1):13–7.

    Article  Google Scholar 

  54. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94(5):1612–7.

    Article  CAS  Google Scholar 

  55. Capen CC, International Agency for Research on Cancer, World Health Organization. Species differences in thyroid, kidney and urinary bladder carcinogenesis. International Agency for Research on Cancer: Lyon; 1999.

    Google Scholar 

  56. Truong T, Orsi L, Dubourdieu D, Rougier Y, Hemon D, Guenel P. Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area. Am J Epidemiol. 2005;161(11):1056–65.

    Article  Google Scholar 

  57. Zhu J, Zhu X, Tu C, Li YY, Qian KQ, Jiang C, et al. Parity and thyroid cancer risk: a meta-analysis of epidemiological studies. Cancer Med. 2016;5(4):739–52.

    Article  Google Scholar 

  58. Zhou YQ, Zhou Z, Qian MF, Gong T, Wang JD. Association of thyroid carcinoma with pregnancy: a meta-analysis. Mol Clin Oncol. 2015;3(2):341–6.

    Article  CAS  Google Scholar 

  59. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol. 2000;24(5):623–39.

    Article  CAS  Google Scholar 

  60. Farrell E, Heffron C, Murphy M, O'Leary G, Sheahan P. Impact of lymphocytic thyroiditis on incidence of pathological incidental thyroid carcinoma. Head Neck. 2017;39(1):122–7.

    Article  Google Scholar 

  61. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955;70(2):291–7.

    Article  CAS  Google Scholar 

  62. Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab. 2013;98(2):474–82.

    Article  CAS  Google Scholar 

  63. McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2012;97(8):2682–92.

    Article  CAS  Google Scholar 

  64. Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol. 2002;10(2):141–6.

    Article  Google Scholar 

  65. Mechler C, Bounacer A, Suarez H, Saint Frison M, Magois C, Aillet G, et al. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Br J Cancer. 2001;85(12):1831–7.

    Article  CAS  Google Scholar 

  66. Sheils OM, O'Eary JJ, Uhlmann V, Lattich K, Sweeney EC. ret/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol. 2000;8(3):185–9.

    Article  CAS  Google Scholar 

  67. Kim KH, Suh KS, Kang DW, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto’s thyroiditis. Pathol Int. 2005;55(9):540–5.

    Article  CAS  Google Scholar 

  68. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007;204(5):764–73. discussion 73–5

    Article  Google Scholar 

  69. Anderson CE, Graham C, Herriot MM, Kamel HM, Salter DM. CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto's thyroiditis. Histopathology. 2009;55(6):683–6.

    Article  Google Scholar 

  70. Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? Hum Pathol. 2003;34(8):764–9.

    Article  CAS  Google Scholar 

  71. Royer MC, Zhang H, Fan CY, Kokoska MS. Genetic alterations in papillary thyroid carcinoma and Hashimoto thyroiditis: an analysis of hOGG1 loss of heterozygosity. Arch Otolaryngol Head Neck Surg. 2010;136(3):240–2.

    Article  Google Scholar 

  72. Pazaitou-Panayiotou K, Polyzos SA, Mantzoros CS. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes Rev. 2013;14(12):1006–22.

    Article  CAS  Google Scholar 

  73. Mack WJ, Preston-Martin S, Dal Maso L, Galanti R, Xiang M, Franceschi S, et al. A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea. Cancer Causes Control. 2003;14(8):773–85.

    Article  Google Scholar 

  74. Kilfoy BA, Zhang Y, Park Y, Holford TR, Schatzkin A, Hollenbeck A, et al. Dietary nitrate and nitrite and the risk of thyroid cancer in the NIH-AARP Diet and Health Study. Int J Cancer. 2011;129(1):160–72.

    Article  CAS  Google Scholar 

  75. Cerci C, Cerci SS, Eroglu E, Dede M, Kapucuoglu N, Yildiz M, et al. Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med. 2007;53(3):157–60.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrine Surgery, National University Hospital, Singapore, Singapore

    Tan Wee Boon & Rajeev Parameswaran

Authors
  1. Tan Wee Boon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajeev Parameswaran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajeev Parameswaran .

Editor information

Editors and Affiliations

  1. Division of Endocrine Surgery, National University Hospital, Singapore, Singapore

    Rajeev Parameswaran

  2. Department of Endocrine Surgery, SGPGI Hospital, Lucknow, India

    Amit Agarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media Singapore

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Boon, T.W., Parameswaran, R. (2018). Epidemiology of Thyroid Cancer. In: Parameswaran, R., Agarwal, A. (eds) Evidence-Based Endocrine Surgery. Springer, Singapore. https://doi.org/10.1007/978-981-10-1124-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1124-5_4

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1123-8

  • Online ISBN: 978-981-10-1124-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation